RxDoctor Payments Data

George Godwin

Otolaryngology · Decatur, ALNPI 1558342931

Payments from drug & device makers

$2,229in general payments, 2019–2025

Across 88 payments — averaging $25.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medical Device Business Services, Inc.$498
  • GSK$377
  • Acclarent, Inc$373
  • Aerin Medical Inc.$253
  • Regeneron Healthcare Solutions, Inc.$245
  • Optinose US, Inc.$236
  • plus $248 from 7 others

What the payments were for

  • Travel & lodging$29013%
  • Food & beverage$1,84983%
  • Education$904%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,229 in reported general payments places this provider in the 60th percentile of 155 otolaryngology providers in Alabama.

See all otolaryngology providers in Alabama

Medicare billing

Part B allowed, 2024
$167,478
Medicare patients
592
Services billed
5,460

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NucalaMepolizumab23$80,726
Azelastine Hcl178$4,823
Epinephrine14$3,203
Montelukast Sodium241$2,726
Scopolamine12$1,559
Mometasone Furoate30$1,391
Cefdinir55$1,257
Ipratropium Bromide47$1,205
Ofloxacin52$1,099
Fluticasone Propionate76$1,041
Tobramycin-DexamethasoneTobramycin/Dexamethasone12$900
Methylprednisolone108$862
Triamterene-HydrochlorothiazidTriamterene/Hydrochlorothiazid93$853
RizatriptanRizatriptan Benzoate20$391
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav15$209

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKNucala$377$80,72623 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 155 otolaryngology providers in Alabama.

Other otolaryngology in Decatur

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →